Physician profile
Ashley E Gentner
NPI 1912451287
$5,677.59
in general payments reported to CMS, 2019-2025
18 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $818 · 2022: $1,146 · 2023: $1,382 · 2024: $1,351 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,447.17 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $969.64 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $781.41 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $600.76 | 2021-2025 | Trintellix |
| Alkermes, INC. | $421.19 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $376.09 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $241.41 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $221.04 | 2022-2025 | Auvelity |
| Neos Therapeutics, LP | $125.68 | 2021-2025 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $113.36 | 2022-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $88.81 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $74.90 | 2021-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $69.83 | 2024 | |
| Jazz Pharmaceuticals INC. | $38.00 | 2025 | |
| Corium, LLC | $34.40 | 2024 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.19 | 2021 | |
| Corcept Therapeutics | $26.00 | 2023 | Korlym |
| Neuronetics, INC. | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Gentner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.